Vincenzo De Sio

Cardiologist | Interventional Cardiology | PhD Student

[Vincenzo De Sio @v_desio]

Tra poco online!

https://t.co/fU4BhV2jp0

#GDS #trombosi #SIC

@FeliceGragnano @paolocalabro1 @vlgmrc @DFCapodanno @MattiaGalli10 @pcirillo @GargiuloG83 @LeonardoGrisafi @giuliarenda @martinaberteotti

[Davide Capodanno @DFCapodanno]

I wouldn’t exactly call myself a black belt in beta-blockers, but with all this talk of superiority, "non-superiority," and "non-non-inferiority," it’s really enough to get confused. If I interpret correctly the avalanche of trials from the past year, accompanied by the inevitable meta-analysis, the takeaway seems to be that after a myocardial infarction in patients with LVEF ≥40%, those already on a beta-blocker shouldn’t stop it, and those not on one might benefit in the 40–49% range, MAYBE, and hardly beyond 50%. Better go back to antithrombotics, which are simpler.

[Twinkle xu @Twinkle_IMR]

📣New Editorial: P2Y12 Inhibitor Monotherapy in #Coronary Artery Disease: Translating Evidence Into Practice

Explore recent pooled analyses on optimal #antithrombotic strategies after PCI.

🔗https://t.co/xvaf2rxPeY

#Cardiology #InterventionalCardiology #PCI #P2Y12

[Felice Gragnano @FeliceGragnano]

🚀 REBOOT-CNIC and BETAMI-DANBLOCK trials report discordant evidence on the role of beta-blockers in post-MI patients with LVEF >40%. An IPD meta-analysis suggests treatment benefit in those with LVEF 40-49%. What’s your take?

#Pharmacotherapy #ESCCongress 📢
@escardio 📡

[SABOURETCardiologist @SABOURETCardio]

Nice review led by @v_desio with @FeliceGragnano and @paolocalabro1 ☀️

[Hemostasis Today @HemostasisToday]

@FeliceGragnano @paolocalabro1 @v_desio @MattiaGalli10 @SABOURETCardio @GargiuloG83 @vlgmrc @arturocesaro We would like to inform you that your post has been published on Hemostasis Today. Thank you for sharing.
https://t.co/HDsZdh9mSF

[Felice Gragnano @FeliceGragnano]

📍 This review summarizes the latest evidence on #cangrelor and discusses future directions for its application in clinical practice 📝

👉 https://t.co/axuzGUiHsT

@paolocalabro1 @v_desio @MattiaGalli10 @SABOURETCardio @GargiuloG83 @vlgmrc @arturocesaro

#CardioEd #CardioTwitter

[Vincenzo De Sio @v_desio]

@OAE_Publishing @FeliceGragnano Congratulations and good luck!
@FeliceGragnano 🎊

[Felice Gragnano @FeliceGragnano]

🚨📚 I’m excited to share our latest contribution!

🔍 Our new chapter "Prognostic Impact of Bleeding in Interventional Cardiology" explores one of the most pressing challenges in cardiology: the prognostic impact of #bleeding after PCI and TAVI 🩸🧠

🔗 https://t.co/MkrL10oIBE

[Felice Gragnano @FeliceGragnano]

📢 In this updated review, we explore the latest evidence on long-term #antithrombotic therapy in patients with #AFib and #PCI. A practical guide to navigate the balance between ischemic and bleeding risk ⚡⛵🩸

🔗 Read more 👉 https://t.co/eq5o4r5gNp

@paolocalabro1 @v_desio

[European Society of Cardiology Journals @ESC_Journals]

🆕 Long-term Antiplatelet Monotherapy after PCI: Searching for the smart choice 🔥 A new #Pharmapulse now online in #EHJPharmacotherapy 👉 https://t.co/r6aq7fNO8p

@EditorEHJCVP @FeliceGragnano @MattiaGalli10 @v_desio @paolocalabro1

[Giuseppe Andò @giuseppe_ando]

The START registry highlights the real-world applicability of semaglutide for secondary CV prevention in post-ACS patients. With insights from SELECT, it’s time to rethink obesity management beyond weight loss. #Cardiology #Obesity #GLP1 #STARTRegistry
https://t.co/Ta6TVFeLeo

[Genomadix Inc. @GenomadixInc]

Precision medicine in action! 🧬❤️

Join @FeliceGragnano at #ANMCO 2025 on March 28 to explore optimized #DAPT strategies for better patient outcomes! (1)

1. Angiolillo DJ, et al. JACC: Cardiovascular Interventions. 2024;17(22):2639-2663 https://t.co/dDtqVXWiRX.

Check it out 👉: https://t.co/m0wJx84EaS

#Cardiology #Cardio #Cardiotwitter #CardioX #MedTwitter #MedX

[Felice Gragnano @FeliceGragnano]

📢 Antithrombotic therapy in patients with #AHREs: Current evidence and open questions just discussed in a new review article in @IJCardio 📚
https://t.co/GlUUl1csV7

@paolocalabro1 @v_desio @arturocesaro @SABOURETCardio @MattiaGalli10 @pelliccia_f @DrErikGrove #Cardiology

[European Society of Cardiology Journals @ESC_Journals]

Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis. A State-of-the-Art review just published in #EHJ 👉 https://t.co/WYfcuP912E

@RoccoMontone @ehj_ed

[Felice Gragnano @FeliceGragnano]

PRECISE-HBR is a novel #bleeding risk score 🩸developed by augmenting the PRECISE-DAPT score with the ARC-HBR criteria 📊

The new score is superior to current risk tools for bleeding prediction after #PCI and enables #standardized risk stratification in practice 🏥

@CircAHA 📢

[Felice Gragnano @FeliceGragnano]

Can we use "on demand" anticoagulation based on #wearable devices in pts with #AFib and PCI? New data from #INTERMITTENT study now published in @ESC_Journals by @pelliccia_f 📊

[Vincenzo De Sio @v_desio]

Exciting experience the Physiology Course from @CoreAalst 🫀
Let’s start with a new day here at @orsiacademy 🔥

#ANewWave #ORSIAcademy #TPC24 #CoronaryPhysiology

[Felice Gragnano @FeliceGragnano]

#EHJPharmacotherapy 💊
#CardioTwitter #Cardiology 🔥
@ESC_Journals 📚

[Felice Gragnano @FeliceGragnano]

📌 In this update review, we share our thoughts on how to improve #antithrombotic therapy in pts with #AFib undergoing #PCI 💊

✅ Online: https://t.co/pcnQ86v4i7

@paolocalabro1 @GargiuloG83 @giuseppe_ando @Costa_F_8 @v_desio @leonardodeluca @JCM_MDPI

#CardioTwitter #Cardiology